A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for most, there is an urgent need to better identify patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Stratford, Jeran K., Bentrem, David J., Anderson, Judy M., Fan, Cheng, Volmar, Keith A., Marron, J. S., Routh, Elizabeth D., Caskey, Laura S., Samuel, Jonathan C., Der, Channing J., Thorne, Leigh B., Calvo, Benjamin F., Kim, Hong Jin, Talamonti, Mark S., Iacobuzio-Donahue, Christine A., Hollingsworth, Michael A., Perou, Charles M., Yeh, Jen Jen
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903589/
https://www.ncbi.nlm.nih.gov/pubmed/20644708
http://dx.doi.org/10.1371/journal.pmed.1000307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903589/
https://www.ncbi.nlm.nih.gov/pubmed/20644708
http://dx.doi.org/10.1371/journal.pmed.1000307

Ejemplares similares